Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Icecure Medical ( (ICCM) ) is now available.
On April 21, 2026, IceCure Medical reported that preliminary, unaudited U.S. revenue from its ProSense® systems and cryoprobes rose more than 30% in the first quarter of 2026 versus the same period in 2025, reflecting early commercial traction after the FDA cleared ProSense® in October 2025 for local treatment of low‑risk breast cancer in women aged 70 and above. The company said it is expanding its installed base at leading U.S. academic and research hospitals and expects to convert a strong pipeline of prospective customers into new system sales in the second quarter of 2026.
The company highlighted growing clinical and economic validation at the Society of Breast Imaging 2026 Symposium in Seattle, held April 16–19, 2026, where it exhibited ProSense® and took part in a hands-on cryoablation workshop for physicians. An award-winning Massachusetts General Hospital cost-analysis study presented at the meeting showed that liquid nitrogen-based cryoablation, including ProSense®, may cut total treatment costs by more than 50% compared with breast-conserving surgery and support faster recovery, positioning cryoablation as a viable alternative for well-selected early-stage breast cancer patients and potentially strengthening IceCure’s role in value-based breast cancer care.
IceCure also used the SBI forum to advance physician education through a practical “How I Do It” cryoablation workshop covering imaging workup, procedural techniques, indications and implementation strategies. The company plans to report full first-quarter 2026 operating and financial results on May 14, 2026, with the preliminary revenue figures subject to normal quarterly closing procedures and final adjustments that could affect reported outcomes.
The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and shrinking equity) and bearish technicals (price below major moving averages with negative MACD). A more positive earnings-call outlook around regulatory validation and expected commercialization acceleration provides some support, but valuation remains constrained by continued losses and no dividend.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medtech company that develops and markets advanced liquid-nitrogen cryoablation systems for minimally invasive destruction of benign and cancerous tumors. Its flagship ProSense® system, cleared for multiple indications in the U.S., Europe and Asia, targets breast, kidney, bone and lung cancers as an alternative to surgical tumor removal.
ProSense® enables office-based procedures with shorter recovery, less pain and fewer complications than surgery, aiming to enhance value for patients and providers and align with evolving, cost-conscious cancer care models.
Average Trading Volume: 444,889
Technical Sentiment Signal: Sell
Current Market Cap: $24.4M
Learn more about ICCM stock on TipRanks’ Stock Analysis page.